What's new in protein folding? EMBO Workshop: Protein folding and misfolding inside and outside the cell  by Radford, Sheena E
Meeting Review R59
What’s new in protein folding?
EMBO Workshop: Protein folding and misfolding inside and
outside the cell
Sheena E Radford
Address:  School of Biochemistry and Molecular Biology, University of
Leeds, Leeds LS2 9JT, UK.
E-mail:  s.e.radford@leeds.ac.uk
Folding & Design 01 June 1998, 3:R59–R63
http://biomednet.com/elecref/13590278003R0059
© Current Biology Ltd ISSN 1359-0278
An EMBO workshop entitled ‘Protein folding and mis-
folding inside and outside the cell’ was held at St Cather-
ine’s College, Oxford, UK, from 24th to 28th March this
year. The meeting, organised by Chris Dobson (Univer-
sity of Oxford), Chris Leaver (University of Oxford) and
John Ellis (University of Warwick), was attended by 202
scientists and involved more than 30 lectures, as well as
talks chosen from posters and the usual array of poster ses-
sions. The aim of the workshop was to embrace the field
of protein folding in its widest perspective, with talks
ranging from simulations of protein folding, to potential
therapies for folding diseases. The aim of this report is to
summarise for readers of Folding & Design some of the
highlights of the meeting and, in particular, to comment
on the common themes that emerged from the diverse
range of topics embraced. It is not my aim to summarise
individual presentations in detail and I apologise to those
whose work is not discussed here or is mentioned only
briefly. Instead, I shall try to highlight common concepts
and exciting breakthroughs, divided into the three themes
of the workshop: spontaneous refolding; folding in intact
cells; and folding and disease.
Spontaneous refolding
The latest view of protein folding at the molecular level
was the first theme of the meeting. In his introductory
overview of this area, Chris Dobson summarised the state-
of-the-art in experimental methods that can be used to
delineate folding mechanisms; readers of Folding & Design
will already be familiar with many of these. The advan-
tages of a multifaceted approach to understanding folding
mechanisms was emphasised, using lysozyme and acyl
CoA binding proteins as examples, including the use of
stopped flow techniques linked to optical spectroscopy,
such as fluorescence and circular dichroism, as well as the
powerful combination of hydrogen exchange labelling
detected by 1H NMR or electrospray ionisation mass spec-
trometry (ESI MS). It is important, however, to bear in
mind that folding occurs rapidly (for most proteins), het-
erogeneously, and from a denatured state that is by no
means random. Thus, the latest important concept for the
experimentalist is the ‘new view’ of folding, in which we
visualise the folding process as a three-dimensional down-
hill energy search for the native state. Chris Dobson
pointed out that in reality this means that potentially
every molecule in a ‘normal’ refolding experiment (e.g.
using µM protein concentrations) could fold in a unique
way from a different conformation in the denatured state,
but over the total ~1018 molecules in the refolding reac-
tion almost the entire energy landscape is sampled. The
impact and the power of the new view of folding is in our
understanding of species such as the ‘molten globule’ and
early folding intermediates in which the average proper-
ties of the ensemble are measured experimentally. The
new view also highlights the need for experimentalists to
design new experiments to determine the nature of the
energy surface for folding, to bridge the gap between
rather ill-defined views (in experimental terms) that arise
from simple physical-chemical calculations of folding
funnels and the ensemble average view of folding that is
the necessary outcome of current methods of studying
folding reactions.
The language barrier between experimentalists and theo-
reticians is now beginning to be bridged and, as stated by
Martin Karplus (Harvard University), “the most exciting
aspect in folding currently is the collaboration between
theory and experiments that leads to stimulation between
them”. One clear example of this is in the particular views
of energy landscapes described by Chris Dobson, which
have emerged from a collaboration with Martin Karplus;
such energy surfaces are defined in terms of experimen-
tally understandable parameters (average effective energy,
number of native contacts, and a parameter related to the
configurational entropy). A second important contribution
by Martin Karplus has come from simulations of the
folding pathway of chymotrypsin inhibitor II (CI2), the
well studied work-horse from Alan Fersht’s group and the
paradigm for a protein with a simple nucleation condensa-
tion mechanism of two-state folding. By recalculating the
unfolding trajectory many times, Martin Karplus was able
to address the question of whether there is a multiplicity
of folding pathways, even for a protein with a such a
simple folding mechanism. The results show, as perhaps
expected, that multiple pathways exist, but importantly
the average properties of molecules populating different
pathways agree closely with the experimentally measured
averaged ensemble pathway. Using molecular dynamics
simulations, Lorna Smith (University of Oxford) also pre-
sented work that bound theory and experiment. Regions
from lysozyme that are known to be partially folded in
solution were excised from the protein and unfolded using
molecular dynamics. Interestingly, not all regions in the
peptide sequence unfolded completely, but significant
helical structure was retained in two sequences, which
correlate with regions shown by NMR to be helical in a
synthetic peptide corresponding to the same sequence.
Long-range interactions, which could not be pinpointed
by NMR as a result of degeneracy in the spectrum, were
shown in the simulation to stabilise this partially folded
state. This points the experimentalist towards new strate-
gies to test the model. Both of these talks, therefore, high-
light the convergence of experiment and theory and offer
the exciting possibility that theoreticians may now be able
to predict realistic folding mechanisms that can be tested
by experimentalists.
A major breakthrough in our understanding of the behav-
iour of proteins in solution has arisen from the ability to
study them using high resolution NMR methods. Most
recently, the advent of isotope labelling and very high fre-
quency instruments (600 MHz and higher) have allowed
us to start to contemplate the precise nature of the
unfolded states of proteins in solution as well as that of
intermediate partially folded states. Presentations by
Lorna Smith and Peter Wright (Scripps Research Insti-
tute) addressed these issues. Peter Wright described the
latest view of the apo-myoglobin folding pathway gleaned
from triple resonance NMR experiments. Here, the 13Cα
chemical shift and the 15N NOE intensity were used as
probes of the conformational preferences and dynamic
properties of the peptide backbone in denatured apo-
myoglobin, in an equilibrium partially folded state at pH 4
and in the native state. Further insights into the conforma-
tion of the denatured state were presented by Lorna
Smith. She described how a model for the random coil of
proteins and peptides can be derived from a knowledge of
the distribution of short-range NOEs and used with high
accuracy to predict 3JHα and 3Jαβ coupling constants of
these states. Not only is this algorithm important for
understanding the conformation of denatured and partially
folded states, but it can be used to tease out weak, but
important, configurational preferences in proteins that are
functional in ‘so-called’ unfolded states. Lorna Smith used
this approach to show that three regions in fibronectin
binding protein (which belongs to this set of bizarre pro-
teins) have a high propensity for occupying the extended
region of conformational space (over a running average of
five residues). Fascinatingly, all three regions (and no
others) have been shown to be important for activity,
demonstrating that even the unfolded state can harbour
properties that are intimately involved in activity.
Although we have made great strides in our understanding
of how proteins fold, it should be borne in mind that our
current database of knowledge about folding has arisen
from detailed work on only a handful of proteins, that may
not be representative of the thousands of structures in the
protein databank. Thus, we must be careful not to draw
too many general conclusions about folding mechanisms
at this stage. One recurring point that arose at the Work-
shop was the issue of whether intermediates detected
experimentally at equilibrium or kinetically teach us
about mechanistic issues of folding, or whether they repre-
sent trapped states or off-pathway species. In the new
view of folding, the issue of on-pathway or off-pathway
intermediates could be considered irrelevant because all
species populated define the energy surface for folding.
Nevertheless, as stated at the Workshop by Martin Karplus,
an off-pathway intermediate can be defined as one whose
structure does not help in the search for the native state.
The issue then boils down to whether a particular species
is obligate for folding or not. In the case of lysozyme, the
α-domain intermediate is bypassed by about one-quarter
of molecules that fold on a fast track to the native state,
indicating that this species is not required for the ultimate
lysozyme fold. In contrast, Peter Wright presented hydro-
gen exchange labelling and ESI MS data to show that the
apo-myoglobin intermediate is obligate for folding, and data
from my own laboratory shows that for the Greek key pro-
tein apo-pseudoazurin a late and unusually stable inter-
mediate (relative to the native state) is undoubtedly on
the folding pathway. This emphasises that new informa-
tion can be learned from proteins with different folds and
a wide database of folding information will be necessary
before we can answer the simple, but essential, question of
whether there is a universal folding code, or whether each
protein has solved the protein folding problem individually.
The ultimate goal of the protein folder is to be able to
design a sequence de novo that will fold to a unique, stable
and active conformation. Luis Serrano (European Molecu-
lar Biology Laboratory, Heidelberg) presented work at the
Workshop that shows we are now well on the way to
achieving this goal. Thus, a novel mini β-sheet protein
called Betanova, only 16 amino acids in length, was des-
igned using an algorithm that optimises propensities for
β-sheet structure, stabilising non-local interactions, rota-
mer libraries and solubility of amino acid sidechains. From
the 1030 possible combinations, 100 amino acid sequences
emerged and the sequence with the lowest energy was
selected and made as a synthetic peptide. Astonishingly,
the peptide folded into the desired monomeric triple
stranded anti-parallel β-sheet structure, which, as judged
by NMR parameters, has a unique structure. Although the
peptide showed only weak cooperativity in thermal denat-
uration, this might be expected for such a small structure.
This de novo designed triple-stranded β-sheet structure
will certainly be useful for delineation of the interactions
that stabilise β-sheets. Perhaps even more excitingly, how-
ever, it might form a platform on to which functionality,
the ultimate challenge in folding and design, can be built.
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Folding in intact cells
Though wondrous and exciting, it is important to realise
that protein refolding experiments in vitro are only mimics
of the real situation of protein folding in the cell. As we
were reminded in the first lecture of the Workshop by
John Ellis, folding in vivo occurs in a highly crowded envi-
ronment (the concentration of macromolecules in the
Escherichia coli cytoplasm is ~340 mg/ml), and may even
occur co-translationally on polysomes. As a result, the pos-
sibility for misfolding and aggregation are much higher in
vivo than in vitro and the cell has evolved a complex
system involving chaperone proteins, which function to
ensure the success of folding in the otherwise unfavour-
able cellular environment. As the protein sequence data-
base increases in size, so does the number of chaperones.
Thus, for example, 14 hsp70-like proteins are found in
yeast alone and, as John Ellis pointed out, the list of differ-
ent chaperone families now numbers > 20. Nevertheless,
only 10–15% of newly synthesised proteins in E. coli are
thought to fold using the famous GroEL machinery, the
remainder presumably folding spontaneously in a manner
akin to that elucidated in vitro, or perhaps using other
chaperone systems.
Although we now have a detailed knowledge of the struc-
ture of GroEL and its co-chaperone GroES, and even of
the 870 kDa GroEL–GroES complex, the identity of the
proteins that require this chaperonin for folding has
remained elusive. The promiscuous nature of GroEL for
partially folded substrates is well known, but the fact that
so few proteins appear to fold using GroEL leads to the
possibility that the real substrates for the chaperonin in
vivo might be rather limited. Two different lectures at the
Workshop, by Ulrich Hartl (Max Planck Institute, Martin-
sreid) and Art Horwich (Yale University), presented the
first clear cut data on this issue. Ulrich Hartl and coworkers
have used two-dimensional gel electrophoresis to resolve
newly synthesised chains that had been immunoprecipi-
tated with anti-GroEL antibodies. Using modern tandem
mass spectrometry methods the spots on the gel could
then be identified. Art Horwich and coworkers used a
similar analytical approach, but instead of immunoprecipi-
tation a temperature sensitive lethal mutation in GroEL
was used to precipitate, in inclusion bodies, proteins
whose folding is absolutely dependent on a functional
GroEL. Although far from complete (only a few of the
spots have so far been identified), both sets of experiments
identified elongation factor Tu as a substrate for GroEL
and other proteins, including GroEL itself; other elonga-
tion factors, E3 from pyruvate dehydrogenase and compo-
nents of the F1 subunit of the F0F1 ATPase were
identified by one or other of the groups. This now opens
the door to the long awaited biophysical experiments of
the GroEL reaction cycle using a real substrate protein.
Moreover, the realisation that GroEL is essential for the
folding of proteins involved in protein synthesis itself
offers new and exciting possibilities for communication
between chaperonins and protein production.
The apical domain of GroEL and its counterpart in the
thermosome and in the eukaryotic complex, CCT, also
received much attention at the Workshop. In his lecture,
Alan Fersht (University of Cambridge) reviewed pub-
lished data from his laboratory that demonstrated the
potential substrate-binding site on the surface of GroEL
(located by the fortuitous binding of a histidine tag in the
domain construct 191–376 to a neighbouring apical dom-
ain in the crystal) and data suggesting that this domain is
able to act as a mini-chaperone, assisting the refolding of
several proteins in vitro. He emphasised the previously
published work from his laboratory that shorter constructs
are more active than the 191–376 construct, and gave new
examples in which immobilised mini-chaperones are
being used preparatively in the laboratory. New work from
Jean Chatellier in Alan Fersht’s group was also presented
that showed that the shortest apical domain made, encom-
passing residues 193–335 of GroEL, complements a tem-
perature-sensitive mutant of GroEL and supplements the
activity of co-expressed GroEL in lethal GroEL knock-
outs of E. coli. The less active full-length domain (191–
376), as found and also presented in the Workshop by
Ulrich Hartl, does not complement the temperature-sensi-
tive mutants. The reasons for the increased activity of the
‘mini-mini-chaperone’ remain elusive. Nevertheless, the
mini-chaperones have a potential use for refolding over-
expressed proteins and offers exciting potentials for the
refolding of proteins in the biotechnology industry.
Awe-inspiring images of GroEL obtained using cryo-elec-
tron microscopy (cryo-EM) from Helen Saibil’s group
(Birkbeck College) continue to impress us with the mag-
nificent beauty of the chaperonin system. Although at low
resolution, these pictures showed us the first images of the
enormous domain movements that occur when GroES
binds to the GroEL tetradecamer and the method, so far,
is the only way that differences between the nucleotide-
bound and free forms of the chaperonin have been
resolved. In his lecture, Keith Willison (Institute of
Cancer Research, London) showed the first images of the
CCT complex in the presence of ATP, also obtained
using EM. As in its prokaryotic counterpart, huge domain
movements are seen when the CCT rings bind nucleo-
tide. Because no crystal structure of this complex is yet
available, and biophysical data on the conformation of the
bound substrate are still lacking, the EM images provide
the first exciting clues that the mechanism of action of
CCT and GroEL might be similar. In her presentation,
Helen Saibil also presented a 9 Å map of GroEL obtained
from high resolution cryo-EM experiments using angular
reconstitution methods. Comfortingly, the image bears
remarkable similarity to the gross features extracted from
the crystal structure of the chaperonin. The impact of this
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work does not lie in the structure of GroEL itself, however,
but, combined with freeze-quench methods, the technique
offers exciting possibilities to see almost molecular details
of this powerhouse in action.
Watching the folding of the nascent chain as it emerges
from the ribosome is perhaps the ultimate goal for protein
folders in all areas of the field. Just imagine the magnifi-
cence of a molecular graphics picture containing a trans-
lating ribosome, an emerging, possibly partially folded,
nascent chain, which may also be decorated with various
molecular chaperones. Before such a picture could be
drawn, however, the chaperones that associate either with
the ribosome or with the nascent chain, or both, need to be
mapped out. The presentation by Betty Craig addressed
this point, at least for yeast. In elegant work, Betty Craig
(University of Wisconsin) was able to identify that one of
the 14 hsp70 molecules in yeast, named ssb, is a ribo-
some-associated chaperone that also binds to the emerg-
ing nascent chain. Bernd Bukau (University of Freiburg)
reminded us, however, that the situation in translating
ribosomes in prokaryotes might be quite different
because there is no direct equivalent to ssb in E. coli. The
ribosomes themselves might also be important for folding
the nascent chain. Indeed, as pointed out by Boyd Hard-
esty (University of Texas at Austin), the 50S subunit of
E. coli ribosomes, and specifically, the 23S RNA, is
capable of assisting the folding of rhodanese, at least in
vitro. Boyd Hardesty’s experiments also suggest that the
elongation factors EF Tu and EF Ts may be involved in
folding. Again, the situation in vivo might be quite differ-
ent because (as pointed out at the meeting by Ulrich
Hartl) newly synthesised rhodanese is critically depen-
dent upon GroEL and GroES. So, how far off is the ulti-
mate goal? In exciting experiments using ESI MS, Chris
Dobson showed that is now possible to obtain mass spec-
tra from intact ribosomes and that the individual compo-
nents can be identified in the forest of peaks. It seems that
we now have the tools to tackle the real issue of co-trans-
lational protein folding, and the ultimate goal of deter-
mining the structure of the nascent chain as it emerges
from the ribosome may be within our grasp.
Folding and disease
Protein folding diseases brought the Workshop to a dra-
matic conclusion with a day-long session bringing together
medics, biophysicists and biochemists in the common quest
to find treatments for these currently incurable illnesses.
Protein aggregation was a central theme in the session,
which, rather than being considered merely a nuisance to
in vitro folders, has now caught on as one of the hottest
topics in folding! The role of the molecular biophysicist
in folding diseases is an important one because it is only
once we can understand the molecular events that occur,
for example early in amyloidosis, that new ideas for the
generation of novel therapies will emerge. Using purified
proteins and a battery of biophysical methods that in vitro
folders have been using for years, we are now beginning
to gain insights into the properties of proteins that make
them misfold. Jean Baum (Rutgers University) used state-
of-the-art NMR methods to study the effect of mutations
in collagen that cause osteogenesis imperfecta. In a feat using
real-time NMR, the process of collagen triple-helix assem-
bly could be followed at atomic resolution in real time
and the effect of mutations in perturbing this process at
the molecular level was revealed. Biophysical methods
were also used by Phillip Thomas (University of Texas
Southwestern) to analyse the ∆F508 mutation in CTFR
that causes cystic fibrosis. Again, the mutation was also
shown to result in a destabilised protein with perturbed
folding kinetics.
A similar theme also emerged from biophysical studies of
proteins involved in amyloidosis. Mark Pepys demon-
strated (through collaborative work with Chris Dobson
and colleagues) that mutations in human lysozyme that
cause amyloidosis are destabilising and decrease the coop-
erativity of the native fold. Jeff Kelly (Scripps Research
Institute) presented data to show that amyloid-causing
mutations in transthyretin (TTR) result in an increase in
the concentration of the amyloidogenic TTR monomer
relative to the normal tetramer, coupled with a massive
(1000-fold) increase in the rate of unfolding of the
monomer. In addition, using hydrogen exchange moni-
tored by ESI MS Carol Robinson (University of Oxford)
was able to study the monomeric form of wild-type and
the Val30→Met amyloidogenic mutant of TTR, revealing
a decrease in protection of the monomeric state of the
amyloidogenic variant, consistent with the hypothesis that
edge-strand peeling could initiate aggregation. Using the
latest QTOF mass spectrometer Carol Robinson was also
able to show fascinating data about the early stages of
aggregation of insulin. As she pointed out, the power of
the QTOF lies in its ability to detect and resolve high
molecular weight species, and using this instrument a
range of aggregated states up to 14 subunits in size could
be seen in the insulin solution immediately after the pH
was reduced to 2.0. The precise nature of the species and
its involvement in amyloid formation has yet to be deter-
mined; nevertheless, this work demonstrates the potential
of ESI MS for the delineation of the important early stages
in the aggregation process. Other highlights in this session
came from Valerie Daggett (University of Washington)
who described how molecular dynamics simulations have
now reached the stage at which useful information about
the early stages of aggregation might be gleaned, David
Eisenberg (University of California, Los Angeles), who
described how a model involving domain swapping might
provide a route to the production of ordered fibrils, and
Max Perutz (University of Cambridge) who described
how polar zippers might be responsible for fibril formation
in Huntingdon’s disease. Finally, Chris Dobson showed
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a wonderful three dimensional image of a protein fibril,
obtained by Helen Saibil using cryo-EM. The fibril was
made from an SH3 domain at acidic pH. Although not
associated with any disease, this is the first detailed cryo-
EM image of a fibril and gives hope for a fuller picture of
the structure of amyloid in the future.
What are the possibilities for potential therapies for amy-
loidosis? As detailed by Mark Pepys, several strategies
can be envisaged, including suppressing the production
of the amyloid precursor, preventing amyloid formation
and increasing amyloid degradation. Suppression of the
production of the amyloid precursor has been taken up by
Jeff Kelly. In his lecture he described how stabilising
native TTR by binding an analogue of thyroxine (the
natural ligand) prevents amyloidosis in vitro, and the
results in a mouse model are also very encouraging.
There was also encouraging news from Byron Caughey
(NIAID Rocky Mountain Laboratories) who presented
data that a short peptide from the prion protein (PrP) is
able to inhibit the conversion of soluble human prion
protein to the insoluble form. Finally, using the third
strategy mentioned above, Mark Pepys has developed a
potential universal treatment for amyloidosis that is based
on the observation that serum amyloid P component
(SAP) binds to most amyloid deposits in vivo and protects
the fibril from degradation. Thus, by stripping SAP off
the fibrils the aggregates are degraded naturally, presum-
ably by phagocytosis. Drug screening has produced a
compound with the desired properties and the work has
progressed as far as mouse models, in which the com-
pound was also effective as an anti-amyloid. We now wait
with bated breath to discover the results of trials with the
compound in man.
Summary
So what did we learn from the meeting in Oxford? For
me, the most exciting aspect was the power of an inter-
disciplinary approach that is now able to link theoretical
simulations of folding to experiments in vitro and in vivo,
and ultimately to the solution of a medical problem in
man. The prospects for the future are exciting. New
protein sequences are emerging almost daily through the
various genome projects and the crystallographers con-
tinue to excite us with new and ever more complex struc-
tures at atomic resolution. The ability to tackle large
protein assemblies by combining different structural
approaches and to understand the conformational prefer-
ences of molecules that even lack a unique structure
using NMR also bode well for the future. It is perhaps
now only a matter of time before we will start to see pre-
dictions of folding mechanisms ab initio, images of
nascent chains emerging from ribosomes, and new thera-
pies for folding diseases. What is clear is that the rapid
innovations in this dynamic field will make for many
exciting workshops to come!
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